Testing lab
ARL Bio Pharma
ISO/IEC 17025:2017 accredited and FDA-registered analytical laboratory in Oklahoma City with DEA licensing for all schedules (I-V). Established in 1998 with over 25 years serving the pharmaceutical industry. Follows USP, FDA, and ICH guidelines for comprehensive analytical and microbiological testing.
Last updated
About ARL Bio Pharma
ISO/IEC 17025:2017 accredited and FDA-registered analytical laboratory in Oklahoma City with DEA licensing for all schedules (I-V). Established in 1998 with over 25 years serving the pharmaceutical industry. Follows USP, FDA, and ICH guidelines for comprehensive analytical and microbiological testing.
Written for the operator's previous directory and reproduced unchanged (markup and emoji stripped). Ported observed .
What it tests
- HPLC
- High-performance liquid chromatography for purity and potency analysis.
- ICP-MS Mass Spectrometry
- Inductively coupled plasma mass spectrometry for elemental analysis and heavy metals.
- Heavy Metals
- Heavy metals screening per USP guidelines.
- Microbial Testing
- Comprehensive microbiological testing services.
- Potency
- Potency testing for pharmaceutical and compounded preparations.
- Residual Solvents
- Residual solvent analysis per ICH Q3C guidelines.
- HPTLC
- High-performance thin-layer chromatography for identity testing.
- PCR
- Polymerase chain reaction testing for biological identity confirmation.
- Stability Studies
- ICH-compliant stability testing programs.
Accepted sample types
- Pharmaceutical products
- Compounded preparations
- Dietary supplements
Turnaround
- Standard
- Not on file
- Rush
- Not on file
Pricing
No pricing on file.
Accreditation
- ISO/IEC 17025:2017 — A2LA
- FDA Registered — FEI 3003644883
- DEA Licensed — RA0230603, Schedule I-V
Strengths and weaknesses
Where it does well
- ISO 17025 accredited with FDA registration
- DEA licensed for all schedules
- 25+ years serving pharmaceutical industry
- Comprehensive analytical and microbiological testing
- Follows USP/FDA/ICH guidelines
Where it falls short
- Not specifically peptide-focused
- Pricing not transparent
Carried verbatim from the source directory's editorial review, observed .